According to the Medicine Intelligence Data Investment Pattern Database, Sonavex, an innovative ultrasound technology company, recently announced the completion of a $15 million (contract RMB 106 million) Series A-2 financing to support its ultrasound technology. This round of financing has attracted several new investors and received strong participation from existing shareholders and industry veterans.

Sonavex is a medical device company located in Baltimore, Maryland, spun off from Johns Hopkins University. Sonavex focuses on developing innovative ultrasound solutions to provide critical visual and quantitative data, improve patient treatment outcomes, and reduce healthcare costs.

Medical ultrasound technology is a crucial imaging diagnostic tool in modern medicine, playing a crucial role in clinical diagnosis and treatment. However, there are still some technical limitations in traditional ultrasound technology, such as limited resolution and imaging quality due to factors such as sound wave frequency and probe size; Real time imaging and high frame rate are crucial for applications such as surgical guidance and cardiac examination, but traditional ultrasound systems may have limitations such as insufficient speed to meet these requirements.

Based on this background, Sonavex has launched a product combination of EchoMark soft tissue markers and EchoSure automatic ultrasound equipment after years of research and development, which are protected by multiple patents. These two products also have multiple advantages:

 EchoMark soft tissue marker
Sonavex's soft tissue marker is an echogenic implant made from absorbable polymers, with a unique shape and special reflective properties for ultrasound. These characteristics help to accurately mark surgical positions through ultrasound imaging and perform subsequent procedural analysis, such as vascular anastomosis.
Moreover, the EchoMark soft tissue marker adopts a special design that enables unique 2D cross-sections and geometric features to be generated from each observation angle. Absorbent polymers have a long history of use in sutures and medical devices. This polymer can dissolve in the human body and typically undergoes biodegradation within 18 to 24 months.

On June 6, 2018, EchoMark and EchoMark LP (low profile) soft tissue markers were approved by the US FDA.

 EchoSure automatic ultrasound equipment
EchoSure is an ultrasound diagnostic system that can automatically detect key vascular parameters such as blood flow, vessel diameter, and depth. These data are crucial for evaluating the maturity and function of arteriovenous fistulas, helping doctors determine the optimal dialysis pathway and intervene in a timely manner to improve surgical success rates.

The EchoSure system combines 3D ultrasound imaging and advanced deep learning algorithms to automatically monitor visual and quantitative blood flow after surgery. When used in conjunction with EchoMark markers, nurses can easily monitor patients in dialysis clinics without ultrasound training, collecting volume flow, diameter, and depth information of arteriovenous fistulas to assist in maturity assessment.

Moreover, the EchoSure application also allows surgeons to remotely monitor patients through mobile devices. The combination of Sonavex's EchoSure and EchoMark technology platforms provides medical professionals with a new tool to collect important vascular parameters required for assessing the maturity of arteriovenous fistulas in dialysis clinics, thereby improving the standard of care for dialysis patients, reducing the time it takes for arteriovenous fistulas to mature, and lowering the cost of managing dialysis patients.

In March 2019, the EchoSure system was approved by the US FDA.

This round of financing is expected to use funds to collect clinical evidence for the product, including recruiting 304 patients for randomized controlled trials. It is worth mentioning that since 2019, Sonavex has received three grants, all from the National Institutes of Health in the United States. The funds are mainly used to support Sonavex's further development of EchoGuide and to fund the activities required for clinical EchoGuide trials and obtain regulatory approval.

Source: https://news.yaozh.com/archive/44469.html